Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sarcoma

4341 - Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)

Date

09 Sep 2017

Session

Sarcoma

Presenters

Filip Janku

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

F. Janku1, A.R.A. Razak2, M.S. Gordon3, D. Flynn4, M. Kaufman4, J. Pitman5, B. Smith4, N. Somaiah6, J. Jennings7, S. Salah2, D. Westwood5, D. Greensmith5, J. Jacobson5, O. Rosen5, S. George7

Author affiliations

  • 1 Investigational Cancer Therapeutics, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Cancer Clinical Research Unit, Princess Margaret Cancer Centre, M5G2M9 - Toronto/CA
  • 3 Medical Oncology, HonorHealth Research Institute, Scottsdale/US
  • 4 Research, Deciphera Pharmaceuticals, 66044 - Lawrence/US
  • 5 Clinical Research And Development, Deciphera Pharmaceuticals, 02451 - Waltham/US
  • 6 Department Of Sarcoma Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 7 Center For Sarcoma And Bone Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4341

Background

Approved TKIs primarily inhibit either the KIT ATP binding pocket (exon 13/14) or a subset of activation loop mutations (exon 17/18) and do not demonstrate activity across both regions known to cause imatinib resistance in GIST. This leaves significant liabilities in inhibitory coverage of known KIT resistance mutations. DCC-2618 is a potent kinase switch control inhibitor active across a broad range of mutations which emerge on treatment with approved TKIs.

Methods

This is a dose-escalation study of oral DCC-2618 (QD or BID q28 days) followed by an expansion cohort in pre-treated TKI resistant GIST. During the escalation phase, FDG-PET scans were performed at baseline and after 3 wks of therapy; CT scans every 2 cycles. Next generation sequencing (NGS) of plasma cell-free (cf) DNA was performed throughout the study to quantify KIT, PDGFRa and other molecular alterations. Concordance of mutational status between plasma cfDNA and tumor tissue was assessed.

Results

33/42 pts enrolled had KIT (30) or PDGFRa- (3) driven GIST and received daily doses ranging from 40-400 mg. Mean prior lines of therapy was 4.8. The dose selected for expansion was 150 mg QD. Safety for all 42 pts was as follows: grade (G) 3/4 adverse effects (regardless of attribution, occurring in > 1 pt) included anemia (15), asymptomatic lipase increase () (7), hypertension (4), creatine phosphokinase (CPK) (2), lower GI hemorrhage (2). Two of the G3/4 lipase at 100 mg BID and 200 mg BID and one CPK at 150 mg QD were DLTs. Of 19 pts with KIT mutant GIST assessed by FDG PET, 15 (79%) had a partial metabolic response per EORTC criteria. 2 out of 23 evaluable patients showed RECIST partial responses (PRs) and 6 out of 11 evaluable patients at doses of ³100 mg/d had RECIST progression free survival of > 6 months (5 pts on therapy at ³Cycle 10). NGS of plasma cfDNA revealed a reduction of mutation allele frequency (MAF) in exons 9, 11, 13, 14, 17 and 18.

Conclusions

DCC-2618 showed encouraging disease control with objective responses and prolonged stable disease in heavily pre-treated GIST patients. The notable decreases in MAF of resistance mutations across all exons supports the use of DCC-2618 beyond imatinib resistance.

Clinical trial identification

NCT02571036

Legal entity responsible for the study

Deciphera

Funding

Deciphera

Disclosure

F. Janku: Research funding: Deciphera; Scientific Advisory Board: Deciphera. D. Flynn, M. Kaufman: Full-time employee of Deciphera Pharmaceuticals. J. Pitman, B. Smith: Full-time employee of Deciphera Pharmaceuticals, stock options at Decipher Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.